Dingwei Ye

Dingwei Ye is Professor and Chair of the Department of Urology at Fudan University Shanghai Cancer Center. He is China's leading uro-oncologist, and his department runs the Chinese arms of major prostate and bladder cancer trials, including studies of androgen receptor pathway inhibitors such as enzalutamide, PARP inhibitors, and the antibody-drug conjugates enfortumab vedotin and disitamab vedotin in urothelial cancer. His publications include trials of abiraterone plus prednisone and of apalutamide in metastatic castration-sensitive prostate cancer, including the LATITUDE study. His interests span prostate, bladder and kidney cancer and urologic surgery.